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Microalbuminuria as a predictor of myocardial infarction in a
Mexican population: The Mexico City Diabetes Study.
Objective. Our objective was to evaluate whether microal-
buminuria predicts myocardial infarction (MI) in a Mexican
population.
Methods. The study was a prospective, population-based
cohort. Baseline examination was carried out in 1989; the
first follow-up in 1993 and the second in 1997. All men and
non-pregnant women between 35 and 64 years of age at the
start of the study were considered eligible. Clinical, anthro-
pometric, and laboratory characteristics were evaluated. All
patients with macroalbuminuria at baseline were excluded
from the present analyses, as were all prevalent cases with
MI. Remaining patients were classified as with or without mi-
croalbuminuria. Incident cases of MI were identified during
follow-up phases using an electrocardiogram (according to the
Minnesota Code) or the death certificate (in which underlying
cause of death was listed as MI, Causes of Death codes 410.0-
410.9).
Results. From 2196 individuals, 1586 satisfied the inclusion
criteria. Two hundred fifteen (13.6%) had microalbuminuria,
and 1371 (86.4%) did not. During follow-up, 10 patients with
microalbuminuria and 31 patients without microalbuminuria
developed an MI. Using robust logistic regression, the proba-
bility of developing MI, adjusting by Framingham score, was
estimated to be 1.90 (95% CI,.97–3.72) times higher in patients
with microalbuminuria as compared with patients without mi-
croalbuminuria.
Conclusion. We found that in a Mexican population the re-
lationship between microalbuminuria and incidence of MI was
borderline statistically significant after adjusting for other car-
diovascular risk factors.
Resumen
Objetivo. Evaluar si la microalbuminuria predice el infarto al
miocardio en la poblacio´n mexicana.
Disen˜o y Me´todos. El studio fue prospectivo, poblacional
y de cohorte. La evaluacio´n inicial se llevo´ a cabo en 1989;
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el primer y segundo seguimiento se realizaron en 1993 y
1997, respectivamente. Individuos del sexo masculino y mu-
jeres no embarazadas, con edades entre los 35 y 64 an˜os se in-
cluyeron en el estudio. Se evaluaron sus caracterı´sticas clı´nicas,
antropome´tricas y laboratoriales. Se excluyeron sujetos que
presentaron macroalbuminuria y/o infarto al miocardio al inicio
del estudio. El resto fueron clasificados como con o sin microal-
buminuria. Los casos incidentes de infarto al miocardio (IM)
fueron detectados durante el seguimiento mediante un elec-
trocardiograma (de acuerdo a la Clasificacio´n de Minnesota)
o el certificado de muerte (causa de muerte IM, co´digos ICD
410.0/410.9).
Resultados. De 2,196 individuos, 1,586 reunieron los crite-
rios de inclusio´n. 215 (13.6%) presentaron microalbuminuria,
en tanto que 1,371 (86.4%) no lo hicieron. Durante el periodo
de seguimiento, 10 individuos con microalbuminuria y 31 sin
ella, presentaron un IM. Mediante el ana´lisis de regresio´n lo-
gistica, la probabilidad de presentar un IM, ajustado con la pun-
tuacio´n Framingham, se estimo´ en 1.90 (95% de IC, 0.97–3.72)
veces mayor en sujetos con microalbuminuria, comparados con
aquellos que no la presentaban.
Conclusio´n. El estudio demuestra que en poblacio´n mexi-
cana, despue´s de ajustar por otros riesgos de enfermedad car-
diovascular, existe una discreta relacio´n entre microalbumin-
uria y la incidencia de IM.
Over the past several decades, morbidity and mortal-
ity due to cardiovascular diseases have increased in the
developing world. This epidemic has had a significant im-
pact in most countries, regardless of economic develop-
ment status, and even in regions in which a decrease in
prevalence has been identified [1].
Microalbuminuria has been reported as an indepen-
dent predictor of cardiovascular disease in patients with
diabetes [2] and hypertension [3]; however, this associa-
tion has also been reported in the absence of those condi-
tions [4]. Several studies suggest that microalbuminuria
could be a surrogate for endothelial damage because it
has been correlated with earlier stages of atherosclerosis
[5].
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Although microalbuminuria has been found to corre-
late with certain cardiovascular risk factors—especially
components of the insulin resistance syndrome [6, 7], in-
cluding insulin levels—in several studies, the association
of microalbuminuria with morbidity and mortality from
cardiovascular diseases has been observed independently
of other cardiovascular risk factors [8].
Identifying accessible early markers that herald car-
diovascular risk in populations that may have the poten-
tial for high morbidity and mortality from ischemic heart
disease might allow effective intervention (eg, early sec-
ondary prevention), thus potentially decreasing morbid-
ity and mortality and, consequently, cost. Every effort
to establish early detection and prevention of cardiovas-
cular disease is highly worthwhile, particularly in eth-
nic groups like the Mexican population, who have a
high prevalence of other cardiovascular risk factors. We
present data demonstrating the value of microalbumin-
uria measurements in assessing the risk of MI.
RESEARCH DESIGN AND METHODS
“The Mexico City Diabetes Study” is a prospective,
population-based investigation that was designed to esti-
mate the prevalence, incidence, and natural history of di-
abetes and cardiovascular risk factors in a low-income ur-
ban population of Mexico City. The study began in 1989.
Since then, 2 follow-up phases have been carried out: one
in 1993, the other in 1997. A homogeneous low socioeco-
nomic area was selected as the study site. Our methods
and procedures have been published previously [9]. The
population included 6 census tracts of Mexico City, for
a total population of 15,532 inhabitants. All individuals
living in each household were listed, and a dataset was
created. A total of 3505 (22.6%) men and non-pregnant
women, from 35 to 64 years of age at baseline, who were
permanently living in the area, were considered to be
eligible. A home interview was conducted with 3319 of
these individuals (94.7%). A clinical and laboratory ex-
amination was obtained in 2282 patients (68.8%). The
first follow-up began in 1993 and was completed in 1994,
approximately 3.5 years later. We were able to interview
1780 individuals (response rate 78%) and examine 1773
(99.6%). The second follow-up phase began in 1997 and
was completed in 1998, approximately 3.5 years after the
first follow-up. A home interview was conducted with
1764 individuals (77.3%); a physical examination was ob-
tained in 1594 (69.9%). For this analysis, we excluded all
prevalent patients with MI according to the Minnesota
Code [10], and all patients with macroalbuminuria at
baseline.
All patients were interviewed in their households and
evaluated at the clinic in the morning. Anthropometrics
were performed by trained personnel. Measures were
taken with patients wearing no shoes and light cloth-
ing. For waist and hip circumferences, metallic tapes were
used, and for skinfold measurements, Lange calipers were
used.
Systolic and diastolic blood pressure was measured us-
ing a random zero sphygmomanometer. Measurements
were taken on the right arm after 5 minutes of rest. Hyper-
tension was defined as systolic blood pressure ≥140 mm
Hg, diastolic blood pressure ≥90 mm Hg, or treatment
with antihypertensive medications regardless of blood
pressure level [11]. Laboratory determinations through-
out the project were performed in the research labo-
ratory of the Division of Clinical Epidemiology at The
University of Texas Health Science Center, Department
of Medicine, San Antonio, TX, USA. The methods and
procedures have been published elsewhere [12]. Fasting
blood glucose, lipids, and insulin were measured before
the administration of a 75-gram oral glucose load, and
glucose and insulin levels were also determined 2 hours
after the glucose load. The diagnostic classification for
diabetes was determined using World Health Organiza-
tion criteria [13]: fasting glucose ≥126 mg/dL; or 2-hour
glucose ≥200 mg/dL; or treatment with oral antidiabetic
medications regardless of glucose level. A urine sam-
ple was taken in the morning to determine proteinuria
(1 + or more) using a dipstick (Combur 10; Boehringer
Mannheim, Mannheim, Germany); if the test was nega-
tive, microalbuminuria was then determined by a semi-
quantitative technique (Microalbumin test tablets; Ames,
Elkhart, IN, USA). Patients were considered to have mi-
croalbuminuria if they had a ++ or greater reaction (ap-
proximately >40 mg/dL).
Incident MI was identified through follow-up phases
by electrocardiogram (ECG) or death certificate. We ob-
tained standard interpretations of each ECG at The Wake
Forest University reading center, EPICARE, using the
Minnesota Code for interpretation. Codes for possible
or probable MI: Q-QS codes of 1.1 to 1.2.7; Q-QS and T
wave codes of 1.2.8 to 1.3, and T wave codes of 5.1 to 5.3.
Death certificate diagnoses were considered valid only
when supported by a clinical report with information re-
lated to the event, and when MI was the underlying cause
of death, according to the International Classification of
Diseases 10a Rev. (ICD 10a, codes 410.0–410.9) [14].
After completing each interview and physical exam-
ination, all participants received a physician-approved,
formal letter at their homes, personally handed to them
by the clinical research nurse, giving the results of their
evaluation, including copies of the laboratory tests and
ECG. When a participant was found to have a specific
diagnosis, the case was referred to his or her physician
or institution where the individual obtained his or her
usual care. Every effort was made to ensure the proper
outcome of such recommendations.
The study protocol was approved by both the Univer-
sity of Texas Health Science Center in San Antonio, TX,
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Table 1. Clinical and laboratory characteristics of patients with or without MA by sex
Men (N = 608) Women (N = 901)
MA Without MA MA Without MA
N = 85 N = 523 N = 125 N = 776
Variable (No.,%) (No.,%) P value (No.,%) (No.,%) P value
Age mean, SD 47.6 (8.5) 46.6 (8.1) 0.3 47.0 (8.5) 46.8 (8.0) 0.9
BMI ≥25 kg/m2 62 (72.9) 381 (72.9) 0.9 108 (86.4) 621 (80.0) 0.09
Diabetic 17 (20.0) 56 (10.7) 0.02 15 (12.0) 106 (13.7) 0.6
Hypertensionb 12 (14.1) 79 (15.1) 0.8 18 (14.4) 119 (15.3) 0.8
Smoking 60 (70.6) 345 (66.0) 0.4 32 (25.6) 204 (26.3) 0.9
Total cholesterol ≥200 mg/dL 43 (50.6) 199 (38.1) 0.03 44 (35.2) 286 (36.9) 0.7
LDL cholesterol ≥135 mg/dL 32 (37.7) 183 (35.3) 0.7 40 (32.3) 258 (33.4) 0.8
Non-HDL cholesterol ≥135 mg/dL 65 (76.5) 384 (73.4) 0.6 82 (65.6) 530 (68.3) 0.5
HDL cholesterol <35 mg/dL 67 (78.8) 398 (76.1) 0.6 69 (55.2) 433 (55.8) 0.9
Triglycerides ≥150 mg/dL 57 (67.1) 376 (72.2) 0.3 76 (60.8) 425 (54.8) 0.2
Fasting insulin level lU/mL (median, 25% and 75%) 11.6 (5.4–23.2) 11.2 (7.3–19.0) 0.5 15.9 (10.2–23.5) 13.0 (8.4–19.6) 0.005
Post load 2-hour insulin level lU/mL 59.8 (28.7–106.7) 55.1 (27.2–99.0) 0.4 99.1 (57.6–167.3) 84.1 (51.6–132.6) 0.02
(median, 25% and 75%)
Abbreviations are: MA, microalbuminuria; SD, standard deviation; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
aDiabetic status: Fasting glucose ≥126 mg/dL or 2-hour glucose: ≥200 mg/dL or treatment with antidiabetic drugs.
bHypertension: systolic blood pressure ≥140 Hg mm or diastolic blood pressure ≥90 mm Hg or treatment with antihypertensive drugs.
Pearson’s v 2 for categorical variables was used.
T test or Kruskal Wallis test for continuous variables were used.
and the Centro de Estudios en Diabetes Institutional Re-
view Boards. All patients gave informed consent.
Statistical analysis
Comparisons of dichotomous variables were per-
formed using chi-square and Fisher exact tests. For con-
tinuous variables, t tests were used. Age and sex-adjusted
means for some variables were calculated by linear re-
gression. Standardized rates of MI and their confidence
interval (95% CI) by age and sex were estimated using
the direct method, with the total population of the study
as the standard population. Incidence rate ratios (IRR)
were estimated by Poisson regression.
The Framingham score was computed using age, sex,
low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol, blood pressure, diabetes, and smoking
[15]. This score estimates the risk of cardiovascular dis-
eases over a 10-year period based on the Framingham
experience of men and women 30 to 74 years of age at
baseline. We used robust logistic regression, with neigh-
borhood as a cluster variable, to estimate the associa-
tion between microalbuminuria and MI, controlling for
other cardiovascular risk factors. Considering the cen-
sus tracts to be homogeneous, we reduced variance due
to the small number of cases. Confounders were tested
by comparing the regression coefficients with the con-
founder included or excluded from the model. The areas
under 2 receiver-operating characteristics curves were de-
termined. The coefficients and their CIs were corrected
through the bootstrapping technique. Stata 8.0 (Stata
8.0, Stata Reference Manual, Release 7; Stata Press,
2003, College Station, TX, USA) was used for statistical
analysis.
RESULTS
The number of patients on whom complete follow-up
data were available was 1509. Of these, 608 (40.3%) were
men and 901 (59.8%) were women. Table 1 shows clinical
and laboratory characteristics of patients with and with-
out microalbuminuria by gender. In men with microal-
buminuria, the proportion of patients with diabetes was
statistically higher (20%) than in men without microal-
buminuria (10.7%). Also, the proportion with hyper-
cholesterolemia was higher in men with microalbumin-
uria (50.6%) compared with men without it (38.1%).
Women with microalbuminuria tended to be more obese
compared with women without it. The median fasting
insulin and 2-hour postglucose load insulinemia were sta-
tistically higher in women with microalbuminuria com-
pared with women without it (fasting insulin 15.9 and
13.0 lU/mL, and 2-hour postglucose load insulin 99.1 and
84.1, respectively). This finding might be related to the
level of obesity observed in women with microalbumin-
uria.
During the follow-up, 10 patients with microalbumin-
uria and 31 patients without microalbuminuria developed
an MI. Table 2 shows the clinical and laboratory charac-
teristics of 19 men and 22 women with MI and those with-
out MI. Patients with MI were significantly older than
patients who did not have MI (51.4 vs. 46.7 years old).
The proportion of patients with MI and microalbumin-
uria (24.4%) was greater than the proportion without MI
(13%). Patients with MI were more often likely to have
diabetes (31.7%). Fasting insulin was higher in patients
with MI than in people without it (16.1 vs. 12.5 lU/mL).
This finding was not seen in the postglucose load insuline-
mia. The rest of the variables were not significantly dif-
ferent between those with and without MI. In addition,
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Table 2. Clinical and laboratory characteristics of patients with or without MI
MI Without MI
(men 19, women 22) (men 589, women 879)
Variable (No.,%) (No.,%) P value
Age mean, SD 51.4 (8.7) 46.7 (8.1) 0.0003
BMI ≥25 kg/m2 35 (85.4) 1137 (77.5) 0.2
Diabetic 13 (31.7) 181 (12.3) <0.001
Hypertensionb 9 (22.0) 219 (14.9) 0.2
Smoking 19 (46.3) 622 (42.4) 0.6
Microalbuminuria 10 (24.4) 191 (13.0) 0.03
Total cholesterol ≥200 mg/dL 18 (43.9) 554 (37.7) 0.4
LDL cholesterol ≥135 mg/dL 16 (39.0) 497 (34.0) 0.5
Non-HDL cholesterol ≥135 mg/dL 30 (73.2) 1031 (70.2) 0.7
HDL cholesterol <35 mg/dL 29 (70.7) 938 (63.9) 0.4
Triglycerides ≥150 mg/dL 25 (61.0) 909 (62.0) 0.9
Fasting insulin level lU/mL (median, 25% and 75%) 16.1 (10.4–25.9) 12.5 (8.0–19.6) 0.02
Post load 2-hour insulin level lU/mL (median, 25% and 75%) 73.5 (51.7–102.1) 73.1 (40.9–124.1) 0.9
Abbreviations are: MI, myocardial infarction; SD, standard deviation; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
aDiabetic status: Fasting glucose ≥126 mg/dL or 2-hour glucose: ≥200 mg/dL or treatment with antidiabetic drugs.
bHypertension: systolic blood pressure ≥140 Hg mm or diastolic blood pressure ≥90 Hg mm or treatment with antihypertensive drugs.
Pearson’s v 2 for categorical variables was used.
T test for continuous variables was used.
Table 3. Age- and sex-adjusted meansa of clinical and laboratory characteristics in patients with and without MI
MI Without MI
(men 19, women 22) (men 589, women 879)
mean (SD) mean (SD) P value
Body mass index kg/m2 28.9 (4.3) 28.1 (4.3) 0.3
Systolic blood pressure mm Hg 120.4 (16.1) 116.6 (15.9) 0.1
Diastolic blood pressure mm Hg 71.7 (10.2) 73.0 (10.1) 0.4
Fasting glucose level mg/dL 124.0 (45.9) 97.3 (45.3) <0.001
Post load 2-hour glucose level mg/dL 119.3 (56.0) 114.0 (55.1) 0.6
Fasting insulin levelb lU/mL 17.5 (2.1) 12.6 (2.1) 0.007
Post load 2- hour insulin levelb lU/mL 71.7 (2.2) 69.1 (2.2) 0.8
Total cholesterol mg/dL 197.0 (43.6) 192.8 (43.1) 0.5
LDL cholesterol mg/dL 127.9 (39.4) 124.3 (38.9) 0.6
Non-HDL cholesterol mg/dL 164.9 (43.5) 160.0 (43.0) 0.5
HDL cholesterol mg/dL 32.2 (8.6) 32.8 (8.5) 0.5
Triglyceridesb mg/dL 190.7 (1.7) 179.8 (1.7) 0.5
Abbreviations are: MI, myocardial infarction; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
aMeans were adjusted by age and sex and their differences were tested using linear regression.
bMeans were estimated with natural logarithm and then transformed in their original units.
Missing values: 8 LDL cholesterol, 2 triglycerides, 2 fasting glucose, 9 fasting insulin, 115 post load 2-hour glucose, and 131 post load 2-hour insulin.
means of some variables adjusted by age and sex were
compared between patients with and without MI. Only
fasting glucose and fasting insulin levels were significantly
different in patients with and without MI (Table 3). The
entire population tends to have relatively low mean high-
density lipoprotein cholesterol and relatively high mean
triglycerides levels.
The cumulative incidence of MI adjusted for age and
gender is presented in Table 4. The incidence of MI
per 1000 inhabitants with direct age standardization was
45.7 for patients with microalbuminuria, whereas patients
without it had half that rate, at 24. Using Poisson re-
gression, the IRR was 1.93 (95% CI, 0.95–3.94) times
higher in patients with microalbuminuria than in pa-
tients without it. The incidence of MI in patients with
and without diabetes was 36.9 and 20.5, respectively.
The IRR was 2.42 (95% CI, 1.22–4.83) times higher in
Table 4. Number of cases and adjusted cumulated incidence of MI
Variable No. of cases Ratea (95% CI) IRRb (95% CI)
Microalbuminuria
Yes 10 45.7 (18.3–73.1) 1.93 (0.95–3.94)
No 31 24.0 (15.6–32.3)
Diabetes statusd
Diabetes 13 46.1 (18.7–73.4) 2.43 (1.23–4.80)c
Non-diabetes 28 21.9 (13.9–30.0)
Hypertensione
Yes 9 32.9 (9.2–56.6) 1.20 (0.56–2.56)
No 32 26.2 (17.3–35.2)
Abbreviations are: MI, myocardial infarction; IRR, incidence rate ratios.
aRate per 1000 inhabitants, adjusted for age and sex by direct standardization
using the total of the sample as standard population.
bIncidence rate ratio using Poisson regression.
cP value < 0.05.
dDiabetic status: Fasting glucose ≥126 mg/dL or 2-hour glucose: ≥200 mg/dL
or treatment with antidiabetic drugs.
eHypertension: systolic blood pressure ≥140 mm Hg or diastolic blood
pressure ≥90 mm Hg or treatment with antihypertensive drugs.
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Table 5. Robust logistic regression for microalbuminuria and MI
Models ORa (95% CI) P value AUC ROC curve (%) P value for model comparisonc
Model I
Microalbuminuria 2.05 (1.00–4.17) 0.05 55.4
Model II
Framingham scoreb 1.91 (1.63–2.23) <0.001 68.5
Model III
Microalbuminuria 1.90 (0.97–3.72) 0.06 68.6
Framingham score 1.88 (1.60–2.21) <0.001
Model IV
Age ≥50 y 2.48 (1.68–3.66) <0.001 67.1
Microalbuminuria 1.93 (0.93–3.99) 0.07
Diabetes status 2.46 (1.56–3.87) <0.001
Models comparison
Model III vs. model II >0.1
Abbreviations are: MI, myocardial infarction; OR, odds ratio; AUC ROC, area under receiver-operating characteristics curves. OR corrected by bootstrap method.
aLogistic regression with robust standard errors using neighborhood as cluster variable.
bThis score includes age, sex, LDL cholesterol or total cholesterol, HDL cholesterol, blood pressure, diabetes, and smoking.
cDifference of 2 areas under ROC curves calculated by method of DeLong.
patients with diabetes than in patients without diabetes.
The incidence of MI was slightly higher in patients with
hypertension, but this difference was not statistically
significant.
The results of the robust logistic regression analysis
for microalbuminuria, other cardiovascular risk factors,
and MI are shown in Table 5. The odds ratio (OR) for
microalbuminuria is of borderline significance. Specifi-
cally, in model III, which includes the Framingham score,
patients with microalbuminuria had an OR for MI of
1.90 (95% CI, 0.97–3.72). When comparing the model
with microalbuminuria and Framingham score (model
III) with the model containing the Framingham score
alone (model II) using likelihood ratio test, it turned
out that the latter model was probably better. Also, the
area under the receiver-operating characteristics curve
was increased minimally in model III compared with
model II. Additionally, ORs corrected by the bootstrap
method were estimated for model III, and the OR for
microalbuminuria remained similar, although its CI was
wider, perhaps because of the small number of cases.
In none of the models did the predictor variables con-
found the OR for microalbuminuria. On the other hand,
the relatively small number of cases precluded an evalu-
ation of the effect of modifiers.
DISCUSSION
The results presented here come from a well-
established cohort followed longitudinally, implemented
with defined methods and procedures, and selected in or-
der to facilitate international comparisons. The method
used in the measurement of microalbuminuria has been
recognized as an acceptable technique for screening pur-
poses because it has good sensitivity (95%) and specificity
(93%) [16]. We do, however, have to concede 2 limita-
tions: 1) the potential influence of urine concentration,
and 2) the fact that we performed the measurement only
once on each examination date. The ECG evaluation,
through a specialized external reading center using the
Minnesota Code, constitutes a standardized methodol-
ogy that allows direct comparison with similar studies.
We elected to incorporate all patients with fatal MI di-
agnosed by death certificate, because we found that this
subset had no significant difference compared with the
subset of survivors of MI diagnosed by ECG, except for
the fact that there were more patients with diabetes in
the group with fatal MI.
It is important to stress the fact that we excluded all
prevalent MIs and all patients with macroalbuminuria at
baseline. Our data reveal that, even with a relatively small
number of events, it is possible to demonstrate the abil-
ity of microalbuminuria to predict MI. This finding has
been demonstrated in other populations [4, 17, 18, 19],
but this is the first report in a Mexican population, which
has a very high prevalence of several cardiovascular risk
factors such as obesity, diabetes, hypertension, and hy-
percholesterolemia.
Although the OR for microalbuminuria adjusted by
Framingham score was of a borderline significance, it is
likely that this result is due to a relatively low number
of events. However, it should be noted that the magni-
tude of both the adjusted and unadjusted associations was
consistent.
We believe that our results, as well as other results pre-
viously published, support the usefulness of microalbu-
minuria to estimate cardiovascular risk in both diabetic
and nondiabetic populations, regardless of hypertensive
status. We recognize the importance of the measurement
of microalbuminuria in the evaluation of patients with di-
abetes as well as in those with hypertension. Perhaps the
time has come for the inclusion of the measurement of
microalbuminuria in the evaluation of all patients after 40
years of age, regardless of their diabetic or hypertensive
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status. This information might enable physicians to im-
plement an intensive lifestyle modification in patients at
high risk.
An interesting contrast comes to our attention, be-
cause it is known that the Mexican population has a
high risk for diabetes as well as for severe microvascular
complications, as evidenced by the prevalence of severe
diabetic retinopathy in comparison with the prevalence
observed in Mexican Americans [20]. This finding is in
contrast with the apparently lower prevalence of MI in
the Mexican population when compared with Mexican
Americans or non-Hispanic whites [21]. Also of interest
is the lower prevalence of hypertension in the Mexican
population when compared with Mexican Americans or
non-Hispanic whites [22]. However, we have previously
demonstrated a high prevalence of microalbuminuria in
this population [7]. It is clear that additional data are re-
quired to clarify this apparently conflicting information.
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